Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424901 · ClinicalTrials.gov registry record · Phase 2
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04424901 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 41 participants.
The verdict
NCT04424901, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage from direct viral entry and proliferation. Dipyridamole has anti-platelet and anti-inflammatory effects. The drug was recently demonstrated to have anti-SARS-Cov-2 effect primarily in vitro. The concentration causing anti-viral effect in vitro is within that in the blood of humans taking this drug. As an oral tablet, it has the advantage of easy administration. Anti thrombotic, anti viral and anti inflammatory actions of this drug may be efficacious and safe in hospitalized subjects
Interventions
- DRUG Placebo
- DRUG Dipyridamole Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-05-03 |
| Est. Completion | 2022-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424901
The ClinicalTrials.gov registry entry for NCT04424901 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04424901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424901 about?
NCT04424901 is a clinical study titled "Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19". Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inf...
What is the current status of trial NCT04424901?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2020-05-03. Estimated completion is 2022-04-24.
What interventions are being tested in trial NCT04424901?
The interventions under investigation include: Placebo (DRUG), Dipyridamole Tablets (DRUG).
Who is sponsoring clinical trial NCT04424901?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.